ArticleBiomedicines2021

Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury.

Podsawee Mongkolpathumrat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.